Introduction : The study of the role of genetic markers of hemostasis disorders in CHF with both preserved (HFPEF) and reduced (HFREF) LVEF in patients with DM2 has not been adequately addressed . Methods : We used “ Genetics of Hemostasis ” kits from the company DNA Technology (USA). Amplification was performed in a DT-Prime 5 amplifier (DNA Technology , USA) for the prothrombin and factor V gene polymorphisms. Results: F13 (rs5985) and fibrinogen (rs1800790): they are more common in patients with HFPEF and DM2 than in the control group and in patients with HFREF ; ITGA2 (rs1126643): was less common in the HFPEF group than in the control group; ITGB3 (rs5918) and PAI-1 (rs1799889) rs5918 are more common than in the control group and HFPEF group. Conclusions : We encourage carrying out this type of studies since they are scarce in the regional literature.